FDA approved the long-acting Altuviiiio therapy for the treatment of hemophilia A
- The first Alzheimer’s disease Aβ and Tau pathological surrounding cell structure and gene expression map
- Magic TCR-T cell therapy: 72% of tumor lesions disappeared
- Monkeypox mRNA Vaccine Competition: U.S. vs. China
- Can an universal mRNA flu vaccine be against all 20 virus subtypes?
- Harvard found why high-protein diet improves sleep quality
- Will cancer vaccines be the direction of curing cancer?
FDA approved the long-acting Altuviiiio therapy for the treatment of hemophilia A
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- COVID-19 has been confirmed to cause DNA damage and cellular aging
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
FDA approved the long-acting Altuviiiio therapy for the treatment of hemophilia A, which only needs to be administered once a week!
On February 23, 2023 , FDA approved the recombinant protein drug Altuviiiio (efanesoctocog alfa) jointly developed by Sanofi and Sobi to prevent and treat hemophilia A.
Weekly Altuviiiio (efanesoctocog alfa ) preventive treatment can significantly reduce the annual bleeding rate in patients with severe hemophilia A【1】.
Hemophilia is an inherited disorder that affects the normal clotting of blood due to a deficiency in clotting factor VIII. People with hemophilia often bleed profusely from injuries and may also have spontaneous bleeding episodes.
Traditional treatment of hemophilia A consists of regular infusions of factor VIII, both prophylactically to prevent bleeding episodes and as needed to control bleeding episodes when they occur.
However, these infusions can be time-consuming, expensive, and can lead to the development of inhibitors that reduce the effectiveness of the treatment.
Altuviiio (Efanesoctocog alfa) therapy is a new treatment option designed to provide longer-lasting protection against bleeding episodes.
Altuviiiio is a modified form of factor VIII that binds to the protein of von Willebrand factor, thereby protecting it from being broken down in the body and thus lasting longer in the body than conventional clotting factor products .
In the body, the modified Factor VIII protein circulates in the blood, where it can help prevent bleeding episodes by promoting blood clotting in response to injury.
The advantages of Altuviiiio in the treatment of hemophilia A are very significant.
By providing longer-lasting protection against bleeding events, Altuviiiio therapy could reduce the time-consuming and costly treatment of frequent Factor VIII infusions.
In addition, Altuviiio ‘s fusion protein design reduces the risk of inhibitor development compared to traditional coagulation factor products .
As a result, FDA-approved Altuviiiio ( efanesoctocog alfa) therapy provides patients with hemophilia A with a more convenient and effective treatment option , and ultimately changes the way we treat hemophilia A and improves patients’ quality of life.
Reference source:
1. von Drygalski A, et al. N Engl J Med . 2023 Jan 26;388(4):310-318. doi: 10.1056/NEJMoa2209226. PMID: 36720133.
FDA approved the long-acting Altuviiiio therapy for the treatment of hemophilia A
(source:internet, reference only)
Disclaimer of medicaltrend.org
